Stryker's CEO Says 2 of Every 3 Knee Robots Now Operate in the US — None Will Be Built in China

Kevin Lobo says Mako now drives two-thirds of Stryker's knee replacements across 2.5 million procedures, even as he rules out Chinese manufacturing over IP theft fears.

Key Takeaways

  • Stryker's Mako robot now performs two of every three knee replacements the company handles, across 2.5 million procedures in 47 countries.
  • CEO Kevin Lobo says Stryker has no plans to manufacture robots in China, calling IP theft 'a massive worry.'
  • Shanghai-based MicroPort MedBot has logged more than 300 orders across 60-plus countries with a 500-unit annual production capacity.
  • Stryker made a roughly $400 million preferred-equity investment in CMR Surgical in October, becoming the exclusive US sales agent for its Versius soft-tissue robot.
  • Stryker cut its 2026 organic sales growth forecast to 6.5-7%, down from 8.3-9.3%.

Stryker chair and CEO Kevin Lobo told a Detroit audience this week that robots now perform two out of every three knee replacements the company handles, a milestone for its Mako platform. In the same appearance, he drew a hard line on where Stryker will never build that hardware: China.

What did Lobo actually say, and where?

Speaking on the "A Tipping Point in Robotics" panel at the Fortune 500 Innovation Forum in Detroit on November 16, Lobo said Mako has now been used in 2.5 million procedures across 47 countries, with one-millimeter precision enabled by haptic boundary controls that stop the robotic arm at the edge of planned bone cuts. He then addressed manufacturing directly: "We have no plans to make any robots in China. The IP is a massive worry," according to Fortune.

Why is China manufacturing suddenly a flashpoint in surgical robotics?

Lobo pointed to Shanghai-based MicroPort MedBot as the clearest example of the competitive pressure building from Chinese manufacturers. MicroPort's Toumai laparoscopic robot has logged more than 300 orders across over 60 countries and is built with an annual production capacity of 500 units. Lobo also said an unnamed major competitor has already taken an equity stake in a Chinese robotics company, and he accused Chinese manufacturers broadly of "knocking off" rival robotic systems rather than developing them independently.

How does this connect to Stryker's own soft-tissue bet?

The comments came weeks after Stryker's roughly $400 million preferred-equity investment in Cambridge-based CMR Surgical, announced in October. That deal makes Stryker the exclusive U.S. sales agent for CMR's Versius soft-tissue robot, which Lobo describes as roughly half the footprint of rival systems, and gives Stryker an exclusive option to acquire CMR outright later. Soft tissue is the market Intuitive Surgical has dominated for two decades with its da Vinci platform, and Stryker is explicitly trying to attack it with a smaller, cheaper machine rather than compete on Intuitive's own large-footprint turf.

What does this mean for the surgical robotics market?

Stryker also trimmed its 2026 organic sales growth forecast to 6.5-7%, down from an earlier 8.3-9.3% range, a reminder that even market leaders in robotic surgery are not immune to broader demand softness. But the China manufacturing stance is the bigger signal for the industry: as Chinese surgical robot makers scale production and chase global orders, Western device makers are drawing manufacturing lines around intellectual property rather than cost, even if it means forgoing cheaper production. Expect that tension, between global scale and guarded IP, to shape how every major surgical robotics player builds its next factory.

Category: Surgical Robotics

Tags: Surgical Robotics CMR Surgical MicroPort MedBot Stryker Mako Kevin Lobo

Related Articles

Frequently Asked Questions

What did Stryker's CEO say about manufacturing robots in China?

Kevin Lobo said Stryker has no plans to build robots in China, citing intellectual property theft risk as 'a massive worry' and accusing Chinese firms of copying rival systems.

How many procedures has Stryker's Mako robot performed?

Mako has been used in 2.5 million procedures across 47 countries, and now performs roughly two out of three of Stryker's knee replacements.

What is Stryker's connection to CMR Surgical?

Stryker made a roughly $400 million preferred-equity investment in CMR Surgical in October 2026, becoming the exclusive US sales agent for its Versius soft-tissue robot with an option to acquire the company later.

Who is MicroPort MedBot?

MicroPort MedBot is a Shanghai-based surgical robotics maker whose Toumai laparoscopic robot has secured more than 300 orders across over 60 countries, with annual production capacity of 500 units.